Joyce Steinberg, MD, FACP, Board-Certified Oncologist and Biopharma Industry Veteran, Joins Thetis Pharmaceuticals
ESSEX, CT – (July 24, 2023) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, announced the appointment today of Joyce Steinberg, MD, FACP, as interim Chief Medical Officer.
Gary Mathias, Chief Executive Officer of Thetis, commented, “Dr Steinberg is a board-certified medical oncologist with over 20 years of biopharma industry experience at Astellas, Abbott, NeoPharm, Searle, and Fujisawa where she specialized in the development of small molecule and biologic therapies. Her experience in designing and overseeing clinical trials will be key as Thetis advances into clinical development of TP-317 for solid tumor cancers and IBD.”
About TP-317
Overview: TP-317 is a patented small molecule drug that delivers Resolvin E1, an endogenous lipid mediator that engages BLT1 as a biased agonist to promote immune homeostasis . Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.
Cancer Program: TP-317 is being developed in cancer as an adjunct to standard of care therapy in advanced colorectal cancer and advanced non-small-cell lung cancer (NSCLC). Its unique myeloid-directed antigen presentation mechanism of action addresses a fundamental need in immunotherapy. Preclinical studies with oral TP-317 in tumor models of these cancers have shown potent single-agent activity, and enhanced efficacy when combined with immune checkpoint inhibitors, chemotherapy and their combination.
IBD Program: TP-317 is being developed in IBD as first-line, oral therapy for moderate-to-severe Crohn’s disease and as second-line, oral therapy for moderate-to-severe ulcerative colitis in patients who are not well controlled on existing therapies. The anticipated high safety premium and unique epithelial repair mechanism of TP-317 supports its use as adjunct therapy to standard-of-care biologics and oral immunomodulators.
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and inflammatory bowel disease. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.
Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.
Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com.